|
Lipids in Health and Disease
|
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
ResearchEpidermal anti-Inflammatory properties of 5,11,14 20:3: Effects on mouse ear edema, PGE2 levels in cultured keratinocytes, and PPAR activationAlvin Berger1,3 , Irina Monnard1 , Markus Baur1,4 , Corinne Charbonnet1,5 , Irina Safonova2 and André Jomard2  1
Nestlé Research Center, Vers-Chez-les-Blanc, 1000 Lausanne 26, Switzerland 2
Galderma R&D, Route des Lucioles, BP 87, 06902 Sophia Antipolis, France 3
Current address: Cytochroma, Inc., Manager Lipidomics™, 330 Cochrane Drive, Markham, Ontario L3R 8E4, Canada 4
Current address: Boehringer Ingelheim Pharma KG, Biopharmaceutical Quality & Development, Head of Manufacturing Alliances, Birkendorfer Str. 65, 88397 Biberach / Riss, Germany 5
Current address: chemin de Vuichardaz 9, CH-1030 Bussigny-près-Lausanne, Switzerland author email corresponding author email
Lipids in Health and Disease 2002,
1:5doi:10.1186/1476-511X-1-5
|
| Published: |
6 December 2002 |
Abstract
Background
5,11,14 20:3 is similar to 20:4n-6 but lacks the internal Δ8 double bond essential for prostaglandin and eicosanoid synthesis. When previously fed to laboratory animals as a gymnosperm seed oil component it has shown anti-inflammatory properties.
Results
Herein, topically applied Podocarpus nagi methyl esters (containing 26% 5,11,14 20:3) were incorporated into mouse ear phospholipids, reduced 20:4n-6, and reduced 20:4n-6- and TPA-induced mouse ear edema. Purified 5,11,14 20:3 was taken up by cultured human skin keratinocytes, reduced 20:4n-6, and reduced PGE2 levels dramatically. Purified 5,11,14 20:3 did not affect PPARα, PPARγ, or PPARδ transactivation.
Conclusions
Topical application of 5,11,14 20:3 to skin surfaces can thus reduce inflammatory processes, most likely by displacing 20:4n-6 from phospholipid pools and reducing downstream inflammatory products derived from 20:4n-6 such as PGE2 and leukotrienes. It could have potential use in treating clinical skin disorders resulting from overproduction of 20:4n-6-derived eicosanoid products. |